McKesson Corporation - Q4 FY2026 Earnings Analysis

Performance Highlights

McKesson reported Q4 FY2026 adjusted EPS of $11.69, a 16% year-over-year increase, with consolidated revenues rising 6% to $96.3 billion and gross profit growing 14% to $3.9 billion, beating expectations across key metrics. Full-year revenues reached $403 billion, up 12%, while adjusted operating profit grew 15% to $6.5 billion and full-year adjusted EPS of $39.11 exceeded the high end of the long-term 13%–16% growth target range.

The single most important driver was specialty pharmaceutical distribution, which powered double-digit operating profit growth across North American Pharmaceutical and fueled a 53% operating profit surge in the Oncology and Multispecialty segment to $385 million, with organic growth of 13% excluding PRISM and Core Ventures contributions. GLP-1 distribution revenues reached $14 billion in Q4, up 22% year-over-year, while Prescription Technology Solutions operating profit grew 13% to $322 million on record biopharma access-season volumes of 3.4 million patients.

Management Outlook and Forward Catalysts

Management issued FY2027 adjusted EPS guidance of $43.80–$44.60, representing 12%–14% growth, or 14%–16% when adjusted for Norway divestiture and prior-year equity gains, squarely at the upper end of long-term targets, signalling confidence in durable operating leverage. The planned Medical-Surgical Solutions IPO, anchored by a $13 billion enterprise valuation and Apollo's $1.25 billion minority investment, is expected to crystallise shareholder value while freeing approximately $5 billion for accelerated share repurchases in FY2027.

The central investor debate centres on whether specialty and GLP-1 distribution growth can sustain momentum after the sequential Q4 volume decline, and whether biosimilar and IRA-driven branded price erosion will compress North American Pharmaceutical margins beyond the guided 5.5%–9.5% operating profit growth range. Bulls will watch Oncology Network provider additions, Ontada data monetisation and RxTS access-solution demand; bears will focus on GLP-1 volume variability, Medical-Surgical separation execution risk and the CFO transition following Britt Vitalone's retirement.